  T cell exclusion from cancers is a major problem for a proportion of patients suffering poor outcomes. Two papers recently published in Nature highlight the negative role of cancer associated fibroblast TGFβ. These studies indicate that TGFβ enables T cell exclusion in a proportion of colorectal and urothelial cancers , and in the latter disease may reduce their response to anti-PD-L1 immunotherapy.